Imaging

#Imaging #SLAS 2021

Visit Yokogawa Life Innovations team at SLAS2021 Digital

Yokogawa Life Innovations says its goal is to solve the needs of researchers, laboratories, and other organisations that seek to improve and automate their processes via a high-content platform. The company will be on booth 142 to discuss how it can help with high-content imaging platforms, microlens dual-spinning disc technology,… Read More

#News

#Imaging

MOBILion awarded grant to resolve biomarkers for Parkinson’s

MOBILion Systems is collaborating with an international research team to identify alterations in the metabolism of selective glycosphingolipids in specific brain regions that contribute to the early onset and progression of Parkinson’s disease (PD). The project is funded by a grant from The Michael J. Fox Foundation and its partner… Read More

#News

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biomarkers #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #Microbiology #Molecular medicine #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

High content screening in action: a powerful tool to identify novel antivirals and vaccines

By Dr Karin Bottcher High content screening (HCS) has played a significant role in infectious disease research and drug discovery to date and can be a strong tool in the age of COVID-19 and beyond. With a focus on viral diseases, this article will describe how HCS has been used… Read More

#Covid-19 #Exclusive Content

#Academic #AI / data analytics / healthtech / informatics #Animal models #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell / tissue culture #Cell culture #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #High Content Screening #High throughput screening #Imaging #Lead discovery #Pharmokinetics #Preclinical #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

The CELL CULTURE innovations increasing drug discovery success

The CELL CULTURE innovations increasing drug discovery success By Helen Stewart-Miller and Abby George Volume 21 Issue 3 - Summer 2020 'Fail early, fail fast' has been a mantra in the pharmaceutical industry for several years and directly impacts the overall strategy of many drug discovery and development programmes. Yet,… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development & optimisation #Assay development optimisation & technology #Biochemistry #Bioengineering #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Combinatorial chemistry #Drug development #Drug discovery #Gene therapy #Genetics / genomes #Genetics / genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Protein chemistry / Proteomics #Regenerative Medicine #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Stem Cell Differentiation

Stem Cell Differentiation By Dr Lilian Hook Stem cells are extraordinary cells, capable of both self-renewal and differentiation to mature somatic cells in vivo and in vitro (1,2). They have many features and advantages which could revolutionise drug development and healthcare applications. Stem cells offer a limitless, consistent supply of… Read More

#Archive

#Analysis #Automation / robotics #Biomarkers #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Clinical specialities #Drug discovery #Drug targets #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Molecular medicine #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Toxicology

Phenotypic Drug Discovery With High Content Screening

Phenotypic Drug Discovery With High Content Screening Sponsored by PerkinElmer Early drug discovery used to be conducted mainly in a target-agnostic fashion, focusing on qualitative readouts from a living system - cells, tissue, or organisms - and asking the question, did this entity affect the phenotype? Target Based or Phenotypic… Read More

#Archive

#Academic #Business #Cell therapy #Cellular assays #Clinical specialities #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Screening #Stem cells #Target validation #Therapeutics #Translational #Translational chemistry

Drug target for aggressive breast cancer found

A team of British and American scientists has discovered a way to slow the growth of breast cancer stem cells in the lab. The study led by Dr Bruno Simões and Professor Rob Clarke from The University of Manchester could eventually lead to combination drug therapies on previously… Read More

#Cancer Research #News

#Academic #Business #Cellular & Molecular biology #Cellular assays #Clinical trials #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Immunology / Virology & Vaccines #Microfluidics #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

UK government advises drug companies to stockpile in case of Brexit disruption

Image: Joshua Coleman According to the Department of Health and Social Care (DHSC), pharmaceutical companies should stockpile six weeks’ worth of goods “to help ensure the continuity of supply of medical goods into and out of the UK”. In a letter to the industry Steve Oldfield, Chief Commercial Officer,… Read More

#Covid-19 #News

#Business #Clinical trials #Drug development #Drug discovery #Imaging #Immunology / Virology & Vaccines #Lead discovery #Regulatory #RNA

GSK and Sanofi to supply US government with 100 million doses of COVID-19 vaccine

Sanofi and GSK have announced a collaborative effort with the US government to accelerate the development and manufacturing of a COVID-19 recombinant protein-based vaccine. The vaccine candidate, developed by Sanofi in partnership with GSK, is based on the recombinant protein-based technology used by Sanofi to produce an influenza… Read More

#Covid-19 #News

#Drug development #Drug discovery #Imaging #Lead discovery #QA/QC #RNA #Screening

NanoImaging Services opens West Coast facility to help grow of its CryoEM network

NanoImaging Services, has opened a new facility close to its San Diego headquarters. The new data collection centre will be the largest private facility for cryoEM data collection globally, says the company, and will serve both national and international clients. Designed to be a data collection farm, this… Read More

#News

#Academic #Biologics / Biotechnology #Business #Cellular assays #Clinical trials #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Microfluidics #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Just-Evotec Biologics to make monoclonal antibody products for COVID-19

Image: Ani Kolleshi The US Department of Defence (DOD) has awarded Evotec’s Seattle-based subsidiary, Just-Evotec Biologics a contract worth $18.2 million to develop monoclonal antibodies (mAbs) for treatment and/or prevention of COVID-19 Under the contract, Just–Evotec Biologics will design a manufacturing process for the production of Current Good… Read More

#Covid-19 #News

#Academic #Assay development optimisation & technology #Business #Cell therapy #Cellular assays #Chemical engineering #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene editing #Gene therapy #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Oncology #RNA #Screening #Stem cells #Therapeutics #Toxicology #Translational #Translational chemistry

Merging two immunotherapies may be more effective treatment against some cancers

Some of the most promising advances in cancer treatment have centred on immunotherapies that rev up a patient’s immune system to attack cancer. However, immunotherapies don’t work in all patients, and researchers have been searching for ways to increase their effectiveness. Now, researchers at Washington University School of… Read More

#Cancer Research #News

#Analysis #Business #Cell therapy #Clinical trials #Drug development #Drug discovery #Gene therapy #High throughput screening #Imaging #Mass spectrometry / NMR #Microbiology #Screening #System biology #Target validation

Avacta updates on clinical validation of Adeptrix COVID-19 diagnostic test

Image: Pille-Riin Priske Avacta has begun work with the UK government’s CONDOR programme to evaluate and clinically validate the high throughput COVID-19 bead-assisted mass spectrometry (BAMS) laboratory assay developed with Adeptrix. The COVID-19 National Diagnostic Research and Evaluation Platform (CONDOR), recently funded by the National Institute for Health… Read More

#Covid-19 #News

#Academic #Assay development optimisation & technology #Business #Cellular assays #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Precision medicine #Preclinical #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

British Patient Capital invests in life-changing biotech companies

British Patient Capital is committing $65m to SV Health Investors’ latest fund, SV7 Impact Medicine Fund (IMF), to turn scientific breakthroughs into biotech companies producing high impact precision medicine drugs for poorly treated diseases. The commitment increases British Patient Capital’s exposure to life sciences and health technology, building… Read More

#Covid-19 #News

#Academic #Business #Cellular assays #Clinical specialities #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Immunology / Virology & Vaccines #Microfluidics #RNA #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Top Ten UK organisations for animal research announced

Understanding Animal Research (UAR), which promotes openness about animal research, has released a list of the ten organisations in Great Britain that carry out the highest number of animal procedures in medical, veterinary and scientific research. These statistics are freely available on the organisations’ websites as part of… Read More

#Covid-19 #News

#Academic #Assay development optimisation & technology #Business #Cellular assays #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Molecular medicine #Oncology #Pathology #Precision medicine #Regulatory #RNA #Screening #Sequencing #Stem cells #Therapeutics #Translational #Translational chemistry

Quantro Therapeutics offers breakthrough oncology drug discovery platform

21 July 2020 Image: Anshu A Thanks to seed financing from Boehringer Ingelheim Venture Fund (BIVF) and Evotec, Quantro Therapeutics will generate a drug discovery pipeline, aiming to transform the precision and scope of cell-based compound screens. With the introduction of ‘Transcriptional Fingerprinting’ to drug discovery, Quantro intends… Read More

#News